ReviewAdvances in experimental medicine and biology2017
Targeting Myeloid-Derived Suppressor Cells in Cancer.
Review in Advances in experimental medicine and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.Proceedings of the National Academy of Sciences of the United States of America · 2019Trial
- The Role of Immunotherapy and Immune Modulators in Hormone-Positive Breast Cancer: Implications for Localized and Metastatic Disease.Journal of clinical medicine · 2025Review
- Markers of Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: New in Molecular Oncology.Asian Pacific journal of cancer prevention : APJCP · 2024Review
- High-Throughput Screening and Proteomic Characterization of Compounds Targeting Myeloid-Derived Suppressor Cells.Molecular & cellular proteomics : MCP · 2023Article
- Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment.Scientific reports · 2023Article
- Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis.Journal for immunotherapy of cancer · 2023Article
- Myeloid-derived suppressor cells (MDSCs): what do we currently know about the effect they have against anti-PD-1/PD-L1 therapies?Ecancermedicalscience · 2023Review
- TInternational journal of molecular sciences · 2022Article
- An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment forScience immunology · 2022Article
- Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.Acta pharmacologica Sinica · 2022Review
- Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma.Theranostics · 2022Article
- Inducible T-Cell Costimulator Ligand Plays a Dual Role in Melanoma Metastasis upon Binding to Osteopontin or Inducible T-Cell Costimulator.Biomedicines · 2021Article
- Histamine in cancer immunology and immunotherapy. Current status and new perspectives.Pharmacology research & perspectives · 2021Review
- Review
- Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice.Cellular immunology · 2021Article
- Inflammation and Myeloid Cells in Cancer Progression and Metastasis.Frontiers in cell and developmental biology · 2021Review
- The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.Nature reviews. Cancer · 2020Review
- The interplay between immunosenescence and age-related diseases.Seminars in immunopathology · 2020Review
- Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment.Cellular & molecular immunology · 2020Review
- Concurrent Control of the Kaposi's Sarcoma-Associated Herpesvirus Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: a New Prospect for the Therapeutic Potential of Lipoxin A4.Journal of virology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid derived suppressor cells (MDSC) represent only a minor fraction of circulating blood cells but play an important role in tumor formation and progression. They are a heterogeneous group of cells that influence the tumor microenvironment by depletion of amino acids, oxidative stress, decreased trafficking of antitumor effector cells, and increased regulatory T and regulatory dendritic cell responses. Investigational treatment strategies targeting MDSCs have attempted to inhibit MDSC development and expansion (stem cell factor blockade, modulate of cell signaling, and target MDSC migration and recruitment), inhibit MDSC function (nitric oxide inhibition and reactive oxygen and nitrogen species inhibition), differentiate MDSCs into more mature cells (Vitamins A and D, all-trans retinoic acid, interleukin-2, toll-like receptor 9 inhibitors, taxanes, beta-glucan particles, tumor-derived exosome inhibition, and very small size proteoliposomes), and destroy MDSCs (cytotoxic agents, ephrin A2 degradation, anti-interleukin 13, and histamine blockers). To date, there are no Food and Drug Administration approved therapies selectively targeting MDSCs, but such therapies are likely to be implemented in the future, due to the key role of MDSCs in antitumor immunity.
Indexed as
Identifiers
29275468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.